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With effective antiretroviral therapy (ART), many HIV-infected people die of diseases other than 
acquired immune deficiency syndrome (AIDS). In particular, coronary artery disease has 
emerged as one of most critical complications of HIV infection and a major cause of morbidity 
and mortality. Although reportedly antiretroviral combination therapy itself may accelerate 
atherosclerosis by enhancing dyslipidemia, most recent epidemiological studies support the 
notion that HIV infection itself contributes to cardiovascular disease. However, it is still a 
mystery how the virus can contribute to cardiovascular disease development even while 
suppressed by ARTs. This review discusses the current understanding of interactions between 
HIV infection and cardiovascular diseases in both clinical and experimental studies with special 
focus on those viral proteins that are still produced by HIV. This will help infectious 
disease/vascular biology experts to gain insights into the pathophysiological mechanisms of 
HIV-associated cardiovascular disease and new trends to treat and prevent cardiovascular disease 
in the HIV-infected population. 




1. Cardiovascular disease (CVD) as a severe complication in HIV patients 
Due to the successful control of HIV viremia and HIV-induced AIDS through antiretroviral 
therapy (ART), CVD has emerged as a leading cause of death in those infected with human 
immunodeﬁciency virus (HIV) [1–3]. Interestingly, HIV-infected individuals have an increased 
risk of CVD both in the absence and in the presence of virologically suppressive ART [4–8]. 
Triant et al. have shown that acute myocardial infarction (AMI) rates and cardiovascular risk 
factors were increased in HIV patients compared with non-HIV patients as indicated by a relative 
risk of 1.75 [95% conﬁdence interval (CI) 1.51–2.02, Pb.0001] for AMI [6]. This increased risk 
is magniﬁed exponentially in the older HIV-infected population. Freiberg et al. analyzed over 
81,000 HIV-positive and HIV-negative individuals from the Virtual Cohort of the Veterans 
Aging Cohort Study from 2003 to 2008, and they showed that even after accounting for other 
traditional risk factors, HIV infection resulted in a 2-fold higher risk of heart attack [8]. 
1.1 Atherosclerosis in the HIV-infected population 
Several studies have addressed the nature of atherosclerotic lesions in the HIV-infected 
population [9–12]. Fitch et al. reported that the presence of plaque and numbers of noncalciﬁed 
plaque segments were in-creased in the HIV-infected group compared with HIV-negative 
controls [9,13]. They concluded that HIV patients without signiﬁcant metabolic abnormalities 
may still develop noncalciﬁed plaque and therefore are at increased risk for coronary artery 
disease (CAD) [9].An-other study assessed the increased risk of atherosclerosis in HIV-infected 
patients by measuring carotid intima-media thickness (IMT) in 145 HIV patients on ART for at 
least 6 months. They revealed that 34 (23.4%) of these patients had carotid plaques that were 
associated with three independent risk factors: old age [odds ratio (OR) 6.16, 95%CI 1.09–34.88; 
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P=.040], hypertension (OR 12.62, 95% CI 1.72–92.49; P=.013), and higher low-density 
lipoprotein cholesterol (OR 1.08, 95% CI 1.01–1.16; P=.039) [10]. 
1.2 Is ART a culprit for HIV-related CVD? 
Although the increased risk of CVD in HIV-infected patients is still not fully understood yet, one 
explanation could be HIV-virus-induced or ART-induced hyperlipidemia and 
hypercholesterolemia, conditions known to promote progression of coronary atherosclerosis 
[14].Indeed, HIV itself [15,16] and a few antiretroviral drugs [17], in particular, HIV protease 
inhibitors, reportedly can cause dyslipidemia in the HIV-positive population, thus contributing to 
the increased risk for CVD. However, the heightened risk of CVD persists even in the current 
treatment era, in which new-generation ART has signiﬁcantly reduced dysmetabolic side effects 
(e.g., insulin resistance, dyslipidemia, and hypertension) [18,19]. 
Currently, there is a controversial discussion whether living with HIV or being on ART produces 
greater cardiovascular risk than being treatment naïve. Untreated HIV infection has been found 
to associate with increased levels of IL-6, a proinﬂammatory cytokine, and a stimulus for hepatic 
C-reactive protein production, a surrogate marker for systemic inﬂammation. Higher levels of 
IL-6 strongly predict cardiovascular events and overall mortality in antiretroviral-drug-untreated 
and antiretroviral-drug-treated HIV infection [20]. This and several other studies suggest that 
ongoing HIV replication and immune depletion signiﬁcantly contribute to increased prevalence 
of elevated inﬂammation biomarkers, altered coagulation, and monocyte activation, and this 
contribution is independent of the substantial contribution from comorbid conditions [21–23]. 
Hsue and colleagues concluded that HIV infection correlates with premature atherosclerosis even 
in the absence of detect-able viremia, overt immunodeﬁciency, and exposure to ART and 
appears to be independent of traditional cardiac risk factors [24]. They found that IMT and C-
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reactive protein was strongly associated with the presence of HIV disease rather than viral load 
or CD4+ T cell count. However, antiretroviral drug exposure was also associated with higher 
IMT [24]. Nevertheless, the Women’s Interagency HIV Study measured Carotid Artery Stiffness 
via ultrasound 6.5 years after measurement of T cell activation and showed that even after the 
initiation of ART, persistently activated T cells strongly correlated with increased carotid artery 
stiffness only in HIV patients, but not in HIV-negative patients [25]. This conclusion that HIV 
itself increases the risk of CVD is further supported by the National Institutes of Health’s 
Strategies for Management of Antiretroviral Therapy study, which utilizes CD4+ cell counts to 
determine the starting and stopping point of intermittent therapy. It reported that the interruption 
of ART was surprisingly associated with increased risk of CVD [26]. This study suggests that 
ART is not the prevailing reason for increased CVD risk in those infected with HIV and that 
HIV viral activities might also contribute. Hansen et al. showed impaired aortic endothelial 
function, increased c-IMT, and increased arterial stiffness in a transgenic (Tg) mouse model 
expressing HIV viral proteins env, tat, nef, vpu, vpr, gp120, and rev. They also found markers 
for vascular remodeling such as decreased elastin content, increased cathepsin K and cathepsin S 
activity, and increased mechanical residual stress in the arteries of these Tg mice [27]. This is in 
line with previous conclusions that HIV infection itself has emerged as an independent 
contributor to CVD in this population [5–7,28]. 
1.3 Effects of smoking, alcohol, and drug abuse for CVD in HIV patients 
Smoking has been found to be an independent factor that is associated with CVD [29,30]. 
Reportedly, 40–70% of HIV-infected population is current smokers. A cohort study of 33,308 
HIV patients showed that the risk of myocardial infarction and CVD decreased with each passing 
year after smoking cessation and that, after 3 years, the risk was almost half that of the ﬁrst year. 
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Smoking tobacco inhibits effective T cells function, which may result in increased risk of 
infection such as pulmonary infections. In addition, HIV infection is associated with a chronic 
state of persistent inﬂammation that increases the risk for CVD, chronic obstructive pulmonary 
disease, and non-AIDS-deﬁning cancers. 
The Veterans Aging Cohort Study showed that, among HIV-infected men, alcohol abuse was 
associated with a higher prevalence of CVD compared with infrequent and moderate drinking, 
even after adjusting for traditional CVD risk factors, ART, and CD4 count [31].In addition, 
recreational drug use including cocaine and methamphetamine contributes to cardiac toxicity 
[32]. 
2. Endothelial dysfunction in HIV patients 
Endothelial dysfunction is associated with an impaired ability of the vascular lining to maintain 
normal homeostasis. In vivo, it predominantly but not exclusively describes the reduced ability 
of arteries to di-late in response to ﬂow-induced nitric oxide (NO) production. In vitro, correlates 
for vascular dysfunction include the NO-quenching reactive oxygen species (ROS), endothelial 
chemokine/adhesion protein expression, and endothelial cell death (apoptosis or necrosis) 
because of the contribution of local inﬂammation and microthromboses to endothelial 
dysfunction in vivo. Endothelial dysfunction can progress to atherosclerosis and has been shown 
to predict future cardiovascular events in most population studies [33,34]. The untreated HIV 
state has been associated with impaired endothelial function [35,36]. This condition can be best 
experimentally assessed using whole virus or viral envelope protein, HIV gp120, which is 
essential for virus entry by binding CXCR4 or CCR5 receptors and by activating these receptors 
to affect T lymphocytes, macrophages, cardiomyocytes, endothelial cells, and central nervous 
system cells [37–40]. HIV gp120 was found in inﬂammatory cells, endothelial cells, and 
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cardiomyocytes in heart tissues from HIV patients with or without HIV cardiomyopathy, while 
HIV DNA or RNA was only in inﬂammatory cells [41]. Studies with HIV envelope as 
recombinant gp120 protein from CXCR4 binding strains have shown that it induces endothelial 
apoptosis by CXCR4-dependent caspase activation [41,42]. Endothelium-derived NO, 
synthesized by the endothelial NO synthase (eNOS), is a major mediator of endothelium-
dependent vasorelaxation and was reduced by HIV gp120 in TNF-α-activated endothelial cells 
[43]. Interestingly, exposure to cigarette smoke and HIV gp120 causes a synergistic increase in 
endothelial cell death [44]. 
However, as discussed in the paragraphs above, ART and its associated reduction in viral 
replication does not fully normalize endothelial activation and dysfunction. Thus, a better 
understanding of mechanisms for continued endothelial dysfunction in ART-treated HIV patients 
is needed to devise new therapeutic strategies to decrease cardiovascular risk in HIV-infected 
patients (Schematic 1). 
2.1 Early HIV-encoded proteins and endothelial dysfunction 
The ongoing viral contribution to vascular dysfunction and CVD may be partially explained by 
the presence of HIV-infected reservoir cells, as reservoir cells and associated cytokine signaling 
are suggested to be important in the development and progression of cardiomyopathy and 
encephalopathy [45]. According to a prevailing view, infected cells hide in tissues such as the 
lymphatic system [46]. However, how can these reservoir T cells possibly inﬂuence 
atherosclerosis development when systemic levels of released HIV proteins and proinﬂammatory 
cytokines are largely reduced when virus production is halted? Certainly, low-level transcription 
of HIV genes continues even after years of ART [47–49], but their relevance for disease is 
unclear. Interestingly, further analysis has shown that the majority of these transcripts represent 
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the “early” HIV genes Tat, Rev, and Nef. As Rev is a nuclear protein [50] with no signiﬁcant 
effects on vascular biology, we will focus on HIV-Tat and HIV-Nef proteins in the following 
paragraphs. 
2.1.1 Effects of HIV-Tat on the vasculature 
HIV transactivator of transcription (Tat) protein, a regulatory protein, is essential for efﬁciency 
of viral transcription [51] and has been implicated in several disease conditions ranging from 
pulmonary hypertension to sleep disorder [41,52,53]. Several in vivo studies suggest that Tat 
causes aberrant cell signaling and leads to altered endothelial cell morphology, gene expression, 
and survival. HIV-Tat has been suggested to play a role in HIV-related Kaposi sarcoma by 
promoting endothelial cell proliferation and tumor angiogenesis [54], and Tat protein was shown 
to promote inﬂammation by activating human endothelial cells [55]. In contrast to its roles in 
angiogenesis, Tat can also cause apoptosis of primary microvascular endothelial cells of lung 
origin via either tumor necrosis factor secretion or the Fas pathway [56]. 
2.1.2 Role of HIV-Nef in endothelial dysfunction 
Negative factor (Nef) is decreased to a much lesser extent than other HIV gene products after 
initiation of antiretroviral treatment [57,58], suggesting that Nef could play a role in mechanisms 
of cardiovascular dysfunction in HIV patients on ART. In general, Nef is known as an important 
HIV pathogenic factor [59]. Nef is also responsible for T cell activation in infected cells [60,61] 
and enhances virus production in vivo [62]. In fact, transgenic mice expressing CD4-promoter-
driven Nef develop a spectrum of pathologies including AIDS-like disease [63] and vasospasm 
in the heart [64], and certain Nef gene variants were linked to pulmonary hypertension [65,66]. 
We have recently reported that HIV-infected T cells are more potent than free virus in activating 
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coronary arterial endothelial cells [67]. There is evidence that this effect is Nef dependent. Nef-
deleted virus shows only residual activity, suggesting that Nef, when compared to all other 
proteins including envelope gp120 and Tat, is the main contributor of HIV-induced endothelial 
activation. 
Our and other groups have demonstrated Nef protein in endothelium of coronary and pulmonary 
arteries in SIV-HIV-Nef-infected macaques [65,67], which showed a relatively high percentage 
of blood cells constantly probing vascular endothelial cells [68], Thus, endothelial cells, 
especially those in developing atherosclerotic plaques, are constantly in direct contact with 
circulating monocytes and T cells and in prime physical position to receive Nef transfer. In the 
proinﬂammatory conditions associated with viremic and even aviremic HIV infection, 
endothelial cell activation leads to increased vascular adhesion protein and chemokine 
expression. This activation promotes T cell and monocyte adherence to endothelial cells, often 
followed by diapedesis. Importantly, Nef-expressing T cells have been shown to exhibit 
increased adherence to endothelial cells based on their impaired diapedesis and migration into 
the subendothelium space [69]. 
In summary, the present review highlights that HIV early-gene-encoded proteins, in particular, 
Tat and Nef, could play a role in the development of CVD in the HIV-infected population 
independent of traditional risk factors (e.g., ART treatment and smoking/alcohol/drug use)(Table 
1). By understanding the mechanisms of these risk factors, we may ultimately discover new ways 
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Schematic 1. Discussed mechanism of HIV-induced endothelial activation and dysfunction in 









Risk factor Main contribution to CAD 
ART Protease inhibitors Induce ROS activation and 
may induce endothelial cell 
apoptosis Induces 
dyslipidemia 
NRTI Increase platelet reactivity 
NNRTI Induce monocytes to adhere 
to vascular endothelium 
Induces dyslipidemia 
HIV Virus Induces MCP-1 production 
Nef protein Induces MCP-1 production, 
ROS activity, and endothelial 
apoptosis eNOS down-
regulation 
Tat protein Induces expression of MCP-1 
and adhesion molecules, 
including VCAM-1, ICAM-1, 
and E-selectin 
Behaviors Smoking, alcohol, and drug abuse Inflammation, immune 
dysfunction, synergy with 
gp120 to induce vascular 
endothelial cell death 
Coinfection Virus such as hepatitis C, human 
herpesvirus 4, and Cytomegalovirus 
Bacteria 
Inflammation 
 
